Welcome to Market Research Explore
MRE

Explore Market Research

Latest market research, industry analysis and market trend reports

Global Atrial Fibrillation Market 2018-2025

Atrial Fibrillation is the most common heart condition causes due to irregular and rapid heart rate and causes poor blood flow and can cause heart failure and stroke. The atrial fibrillation market is estimated to reach USD XX billion by 2025. The market is estimated to decline after 2021 due to the patent expiry of the major drugs with the sales of new drug is estimated to be low. Increased usage of generics, increasing awareness about the disease and growing focus of companies in the emerging nations are some of the key trends in the atrial fibrillation market. Major companies in the industry are focusing on differentiating the products and are also focusing on advertising for sales. Market Dynamics Growing adoption of new oral anticoagulants for the prevention of atrial fibrillation, large products in pipeline, launch of antidotes for new oral anticoagulants in the event of uncontrolled bleeding, increasing patient population, and advancements in technologies are some of the major factors driving the growth of the market in the forecasted period. High cost associated with the development of the novel products, high time required for the product approvals, availability of substitute products, and patent expiry are some of the major challenges for the growth of the market. For example, Boehringer Ingelheim’s Pradaxa United States patent will expire in February 2018. Segmentation by Product Type By drug class, the market is segmented by antiarrhythmic drug and Anticoagulant drug. The majority of the antiarrhythmic drug are currently in the phase II and phase III with large scope for further development of the products. High cost for the development of the products and large time for product approvals, presence of substitutes for the product and lack of reimbursement policies are the major challenges for the growth of the market. The Anticoagulant market has witnessed a lot of new products in the recent years increasing the competition in the industry. Segmentation by Geography North America dominates the global atrial fibrillation market by with United States account for the largest market share in the region. Large prevalence of population, early adoption of anticoagulants are driving the market while high prices of the products is restraining the growth of the market. Europe accounts for the second largest market share in the forecasted period while emerging nations are growing at the fastest growth rate. Scope of the Report Segmentation by Product Type Monoclonal Antibodies Cancer Vaccines Immune Checkpoint Inhibitors Others Segmentation by Cancer Type Lung Cancer Breast cancer Head and neck cancer Melanoma Colorectal cancer Ovarian cancer Others The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles. Why Purchase the Report? • Visualize the composition of the global cancer immunotherapy market with clear distinction between each design type and usage type. • Identify commercial opportunities in the global cancer immunotherapy Market analysing trends and co-development deals. • Excel data sheet with thousands of data points of the global cancer immunotherapy market. • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. • Product mapping in excel for the key products of all major market players Target Audience: • Equipment Suppliers/ Buyers • Service Providers/ Buyers • Industry Investors/Investment Bankers • Education & Research Institutes • Research Professionals • Emerging Companies • Manufacturers

1. Methodology and Scope 1.1 Research Methodology 1.2 Scope of the report 2: Industry Analysis 2.1 Market Drivers 2.2 Market Restraints 2.3 Porters Five Forces 3. Market Overview 3.1 Epidemiology Analysis 3.2 Clinical Trial Analysis 4. Product Pipeline Analysis 5. Segmentation by Product Type 5.1 Pharmacological Drugs 5.1.1 Anti-arrhythmic Drugs 5.1.2 Anti-coagulant Drugs 5.2 Non-Pharmacological Drugs 5.2.1 Catheter Ablation Procedures 5.2.1.1 Radiofrequency Catheter Ablation 5.2.1.2 HIFU Catheter Ablation 5.2.1.3 Catheter Cryoablation 5.2.1.4 Microwave Catheter Ablation 5.2.1.5 Laser Catheter 5.2.2 Maze Surgery 5.2.3 Electric Cardio version 6. Segmentation by Geography 6.1 North America 6.1.1 United States 6.1.2 Canada 6.1.3 Rest of North America 6.2 Europe 6.2.1 United Kingdom 6.2.2 Germany 6.2.3 Spain 6.2.5 Rest of Europe 6.3 Asia-Pacific 6.3.1 China 6.3.2 Japan 6.3.3 India 6.3.4 Australia 6.3.5 Rest of Asia-Pacific 6.4 South America 6.4.1 Brazil 6.4.2 Argentina 6.4.3 Rest of South America 6.5 Rest of the World 7. Competitive Landscape 7.1 Market Player Analysis 7.2 Key Strategies Adopted by Major companies 8. Company Profiles 8.1 Boehringer Ingelheim GmbH 8.2 Bristol-Myers Squibb 8.3 Boehringer Ingelheim 8.4 Daiichi-Sankyo 8.5 Cardio Focus Inc 8.6 Endoscopic Technologies 8.7 Sanofi Aventis 8.8 Johnsons & Johnson 8.9 Ionis Pharmaceuticals 8.10 Otsuka Pharmaceutical 8.11 Pfizer 9. Appendix 9.1 Disclaimer 9.2 Contact Us


  Payment Mode
Single User 3750
Corporate User 7250

  About this Report
Category Pharmaceutical
Published on 1/22/2019
Number of Pages 173
Over all Rating
"Rating is based on 79 reviews"